Status:
COMPLETED
Effects of Dynamine Ingestion on Various Indices of Sustained Energy
Lead Sponsor:
The Center for Applied Health Sciences, LLC
Conditions:
Energy
Eligibility:
All Genders
21-55 years
Phase:
NA
Brief Summary
This study is a randomized, placebo-controlled, double-blind, within-subject crossover trial of 25 men and women. The objective of this study is to assess the effects of Dynamine (methylliberine) supp...
Detailed Description
This study is a randomized, placebo-controlled, double-blind, within-subject crossover trial of 25 men and women. Dynamine (methylliberine) is a caffeine metabolite and purine alkaloid found in the ku...
Eligibility Criteria
Inclusion
- provide voluntary signed and dated informed consent
- in good health as determined by physical examination and medical history
- between the ages of 21 and 55 years
- body mass index (BMI) of 18.5-27 kg•m-2
- agrees to abstain from exercise and alcohol for 24 hours prior to each study visit
- agrees to abstain from coffee and caffeinated beverages for 12 hours prior to each study visit
- normotensive (seated, resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg
- normal seated, resting heart rate (\<90 per minute)
- willing to duplicate their previous 24-hour and fast for 8 hours prior each study visit
Exclusion
- a history of diabetes or pre-diabetes
- a history of malignancy in the previous 5 years except for non-melanoma skin cancer
- prior gastrointestinal bypass surgery
- known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism
- any chronic inflammatory condition or disease
- a known allergy to any of the ingredients in the supplement or the placebo
- currently participating in another research study with an investigational product or have been in another research study in the previous 30 days
- a caffeine intake of three or more cups of coffee or equivalent (\>400 mg) per day
- uses corticosteroids or testosterone replacement therapy (ingestion, injection, or transdermal)
- had any other diseases or conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the participant at increased risk of harm if they were to participate
Key Trial Info
Start Date :
September 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 21 2023
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06048640
Start Date
September 30 2022
End Date
July 21 2023
Last Update
September 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Center for Applied Health Sciences
Canfield, Ohio, United States, 44406